PMID- 24915470
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20191210
IS  - 1541-2563 (Electronic)
IS  - 1541-2563 (Linking)
VI  - 12
IP  - 1
DP  - 2015 Feb
TI  - Minimum clinically important difference in diffusing capacity of the lungs for 
      carbon monoxide among patients with severe and very severe chronic obstructive 
      pulmonary disease.
PG  - 31-7
LID - 10.3109/15412555.2014.898051 [doi]
AB  - BACKGROUND: The minimum clinically important difference (MCID) for diffusing 
      capacity of the lungs for carbon monoxide (DLCO) has not yet been solidly 
      established. METHODS: We used the dataset of surgical cohort of National 
      Emphysema Treatment Trial. Briefly, severe and very severe chronic obstructive 
      pulmonary disease (COPD) patients who were candidate for volume reduction surgery 
      and who could provide sufficient data at 12-month follow-up were included. We 
      used two anchor methods using 6-minute walk distance (6MWD. MCID = 40 m) and 
      forced expiratory volume in 1 sec (FEV1. MCID = 100 ml) as anchors, and two 
      distribution methods. We proposed MCID with a median of estimated values. We 
      estimated MCID for DLCO in raw value and % change from the baseline 
      independently. RESULTS: The surgical cohort included 356 patients, whose average 
      age was 66.6 +/- 5.5 years, and the average % predicted FEV1 was 27.8 +/- 7.3%. The 
      estimated MCID for DLCO in raw value and % change from the baseline were as 
      follows: anchor method (average, 6MWD) 1.2 ml/min/mmHg, 17%; anchor method 
      (average, FEV1) 0.7 ml/min/mmHg, 11%; anchor method (receiver operating 
      characteristic, 6MWD) 1.1 ml/min/mmHg, 10%; anchor method (receiver operating 
      characteristic, FEV1) 1.2 ml/min/mmHg, 3%; distribution method (0.3 units of 
      standard deviation), 0.9 ml/min/mmHg, 11%; distribution method (standard error of 
      measurement), 1.1 ml/min/mmHg. The median of these values was 1.1 ml/min/mmHg and 
      11%. CONCLUSION: We estimated the group-level MCID for DLCO for patients with 
      severe and very severe COPD patients as 1.1 ml/min/mmHg and 11% of baseline DLCO.
FAU - Horita, Nobuyuki
AU  - Horita N
AD  - 1Department of Internal Medicine and Clinical Immunology, Yokohama City 
      University Graduate School of Medicine , Yokohama , Japan.
FAU - Miyazawa, Naoki
AU  - Miyazawa N
FAU - Kojima, Ryota
AU  - Kojima R
FAU - Inoue, Miyo
AU  - Inoue M
FAU - Ishigatsubo, Yoshiaki
AU  - Ishigatsubo Y
FAU - Kaneko, Takeshi
AU  - Kaneko T
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20140610
PL  - England
TA  - COPD
JT  - COPD
JID - 101211769
RN  - 0 (Biomarkers)
RN  - 7U1EE4V452 (Carbon Monoxide)
SB  - IM
MH  - Aged
MH  - Biomarkers/metabolism
MH  - Carbon Monoxide/*metabolism
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pneumonectomy
MH  - *Pulmonary Diffusing Capacity
MH  - Pulmonary Disease, Chronic Obstructive/*physiopathology/surgery/therapy
MH  - Reproducibility of Results
MH  - *Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - differential threshold
OT  - emphysema
OT  - respiratory function tests
OT  - surgery
EDAT- 2014/06/11 06:00
MHDA- 2015/10/27 06:00
CRDT- 2014/06/11 06:00
PHST- 2014/06/11 06:00 [entrez]
PHST- 2014/06/11 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
AID - 10.3109/15412555.2014.898051 [doi]
PST - ppublish
SO  - COPD. 2015 Feb;12(1):31-7. doi: 10.3109/15412555.2014.898051. Epub 2014 Jun 10.